PCN5 COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC): A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

• 作者R Brown; A Benedict; RE Mansel
• 卷第7卷
• 期第6期
• 文件大小64.15KB
• 发表时间2004
• DOI10.1016/s1098-3015(10)65739-7